Parving Hans-Henrik

Top coauthors of Parving Hans-Henrik

Rossing Peter (89 papers)

Tarnow Lise (74 papers)

de Zeeuw Dick (37 papers)

Hovind Peter (27 papers)

Remuzzi Giuseppe (24 papers)

List of Parving Hans-Henrik publications

2016

Gæde Peter, Oellgaard Jens, Carstensen Bendix, Rossing Peter, Lund-Andersen Henrik, et al. 2016. "Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial." Diabetologia doi:10.1007/s00125-016-4065-6
Lindhardt Morten, Persson Frederik, Zürbig Petra, Stalmach Angelique, Mischak Harald, et al. 2016. "Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association doi:10.1093/ndt/gfw292
Zobel Emilie H, von Scholten Bernt J, Lajer Maria, Jorsal Anders, Tarnow Lise, et al. 2016. "High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes." Journal of diabetes and its complications doi:10.1016/j.jdiacomp.2016.07.008
Persson Frederik, Theilade Simone, Eugen-Olsen Jesper, Rossing Peter, Parving Hans-Henrik 2016. "Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes." Journal of diabetes and its complications doi:10.1016/j.jdiacomp.2016.07.003
Persson Frederik, Lindhardt Morten, Rossing Peter, Parving Hans-Henrik 2016. "Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review." Journal of the renin-angiotensin-aldosterone system : JRAAS 17 (3) doi:10.1177/1470320316652047
Schievink Bauke, de Zeeuw Dick, Smink Paul A, Andress Dennis, Brennan John J, et al. 2016. "Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers." European journal of preventive cardiology 23 (7) doi:10.1177/2047487315598709
Kröpelin Tobias F, de Zeeuw Dick, Remuzzi Giuseppe, Bilous Rudy, Parving Hans-Henrik, Heerspink Hiddo J L 2016. "Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease." Journal of the American Society of Nephrology : JASN doi:10.1681/ASN.2015101150
Heerspink Hiddo J L, Persson Frederik, Brenner Barry M, Chaturvedi Nish, Brunel Patrick, et al. 2016. "Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial." The lancet. Diabetes & endocrinology 4 (4) doi:10.1016/S2213-8587(15)00469-6
von Scholten Bernt Johan, Reinhard Henrik, Hansen Tine W, Oellgaard Jens, Parving Hans-Henrik, et al. 2016. "Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria." Diabetologia doi:10.1007/s00125-016-3937-0
von Scholten Bernt Johan, Reinhard Henrik, Hansen Tine Willum, Schalkwijk Casper G, Stehouwer Coen, et al. 2016. "Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria." Journal of diabetes and its complications 30 (2) doi:10.1016/j.jdiacomp.2015.11.005
Nexø Bjørn A, Villesen Palle, Nissen Kari K, Lindegaard Hanne M, Rossing Peter, et al. 2016. "Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci." Immunologic research 64 (1) doi:10.1007/s12026-015-8671-z
Pena Michelle J, Heinzel Andreas, Rossing Peter, Parving Hans-Henrik, Dallmann Guido, et al. 2016. "Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus." Journal of translational medicine 14 (1) doi:10.1186/s12967-016-0960-3

2015

Schievink Bauke, de Zeeuw Dick, Parving Hans-Henrik, Rossing Peter, Lambers Heerspink Hiddo Jan 2015. "The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers." British journal of clinical pharmacology 80 (4) doi:10.1111/bcp.12655
Østergaard Jakob A, Thiel Steffen, Lajer Maria, Steffensen Rudi, Parving Hans-Henrik, et al. 2015. "Increased all-cause mortality in patients with type 1 diabetes and high-expression mannan-binding lectin genotypes: a 12-year follow-up study." Diabetes care 38 (10) doi:10.2337/dc15-0851
Kohan Donald E, Lambers Heerspink Hiddo J, Coll Blai, Andress Dennis, Brennan John J, et al. 2015. "Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy." Clinical journal of the American Society of Nephrology : CJASN 10 (9) doi:10.2215/CJN.00570115
Hjortebjerg Rikke, Tarnow Lise, Jorsal Anders, Parving Hans-Henrik, Rossing Peter, et al. 2015. "IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy." The Journal of clinical endocrinology and metabolism 100 (8) doi:10.1210/jc.2015-2196
Kröpelin Tobias F, de Zeeuw Dick, Andress Dennis L, Bijlsma Maarten J, Persson Frederik, et al. 2015. "Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy." Clinical journal of the American Society of Nephrology : CJASN 10 (3) doi:10.2215/CJN.07780814
Germain Marine, Pezzolesi Marcus G, Sandholm Niina, McKnight Amy J, Susztak Katalin, et al. 2015. "SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes." Diabetologia 58 (3) doi:10.1007/s00125-014-3459-6
de Zeeuw Dick, Anzalone Deborah A, Cain Valerie A, Cressman Michael D, Heerspink Hiddo J Lambers, et al. 2015. "Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial." The lancet. Diabetes & endocrinology 3 (3) doi:10.1016/S2213-8587(14)70246-3
Andrésdóttir Gudbjörg, Jensen Majken L, Carstensen Bendix, Parving Hans-Henrik, Hovind Peter, et al. 2015. "Improved prognosis of diabetic nephropathy in type 1 diabetes." Kidney international 87 (2) doi:10.1038/ki.2014.206
Parving Hans-Henrik, Rossing Peter 2015. "Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy." Nature reviews. Nephrology 11 (2) doi:10.1038/nrneph.2014.238
Parving Hans-Henrik, Persson Frederik, Rossing Peter 2015. "Microalbuminuria: a parameter that has changed diabetes care." Diabetes research and clinical practice 107 (1) doi:10.1016/j.diabres.2014.10.014
von Scholten Bernt Johan, Reinhard Henrik, Hansen Tine Willum, Lindhardt Morten, Petersen Claus Leth, et al. 2015. "Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes." Cardiovascular diabetology 14 doi:10.1186/s12933-015-0225-0

2014

McMullan Ciaran J, Lambers Heerspink Hiddo J, Parving Hans-Henrik, Dwyer Jamie P, Forman John P, de Zeeuw Dick 2014. "Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial." American journal of kidney diseases : the official journal of the National Kidney Foundation 64 (5) doi:10.1053/j.ajkd.2014.06.008
Østergaard Jakob A, Thiel Steffen, Hovind Peter, Holt Charlotte B, Parving Hans-Henrik, et al. 2014. "Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study." Diabetologia 57 (10) doi:10.1007/s00125-014-3332-7
Pedersen-Bjergaard Ulrik, Kristensen Peter Lommer, Beck-Nielsen Henning, Nørgaard Kirsten, Perrild Hans, et al. 2014. "Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial." The lancet. Diabetes & endocrinology 2 (7) doi:10.1016/S2213-8587(14)70073-7
Andrésdóttir Gudbjörg, Jensen Majken L, Carstensen Bendix, Parving Hans-Henrik, Rossing Kasper, et al. 2014. "Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors." Diabetes care 37 (6) doi:10.2337/dc13-2036
de Zeeuw Dick, Coll Blai, Andress Dennis, Brennan John J, Tang Hui, et al. 2014. "The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy." Journal of the American Society of Nephrology : JASN 25 (5) doi:10.1681/ASN.2013080830
Lambers Heerspink Hiddo J, Weldegiorgis Misghina, Inker Lesley A, Gansevoort Ron, Parving Hans-Henrik, et al. 2014. "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)." American journal of kidney diseases : the official journal of the National Kidney Foundation 63 (2) doi:10.1053/j.ajkd.2013.09.016

2013

de Zeeuw Dick, Akizawa Tadao, Audhya Paul, Bakris George L, Chin Melanie, et al. 2013. "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease." The New England journal of medicine 369 (26) doi:10.1056/NEJMoa1306033
Lambers Heerspink Hiddo J, Chertow Glenn M, Akizawa Tadao, Audhya Paul, Bakris George L, et al. 2013. "Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 28 (11) doi:10.1093/ndt/gft445
Persson Frederik, Lu Xifeng, Rossing Peter, Garrelds Ingrid M, Danser A H Jan, Parving Hans-Henrik 2013. "Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?" Journal of hypertension 31 (8) doi:10.1097/HJH.0b013e328362217c
Nielsen Stine E, Schjoedt Katrine J, Rossing Kasper, Persson Frederik, Schalkwijk Casper G, et al. 2013. "Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease." Journal of the renin-angiotensin-aldosterone system : JRAAS 14 (2) doi:10.1177/1470320312460290
Hyvönen Mervi E, Ihalmo Pekka, Sandholm Niina, Stavarachi Monica, Forsblom Carol, et al. 2013. "CD2AP is associated with end-stage renal disease in patients with type 1 diabetes." Acta diabetologica doi:10.1007/s00592-013-0475-9
de Zeeuw Dick, Akizawa Tadao, Agarwal Rajiv, Audhya Paul, Bakris George L, et al. 2013. "Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)." American journal of nephrology 37 (3) doi:10.1159/000346948
Overgaard Anne Julie, McGuire James N, Hovind Peter, Parving Hans-Henrik, Rossing Peter, Pociot Flemming 2013. "Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients." Journal of diabetes and its complications 27 (1) doi:10.1016/j.jdiacomp.2012.06.016

2012

Persson Frederik, Rossing Peter, Parving Hans-Henrik 2012. "Direct renin inhibition in chronic kidney disease." British journal of clinical pharmacology doi:10.1111/bcp.12072
Parving Hans-Henrik, Brenner Barry M, McMurray John J V, de Zeeuw Dick, Haffner Steven M, et al. 2012. "Cardiorenal end points in a trial of aliskiren for type 2 diabetes." The New England journal of medicine 367 (23) doi:10.1056/NEJMoa1208799
Parving Hans-Henrik, Brenner Barry M, McMurray John J V, de Zeeuw Dick, Haffner Steven M, et al. 2012. "Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)." Journal of the renin-angiotensin-aldosterone system : JRAAS 13 (3) doi:10.1177/1470320311434818
Sandholm Niina, Salem Rany M, McKnight Amy Jayne, Brennan Eoin P, Forsblom Carol, et al. 2012. "New susceptibility loci associated with kidney disease in type 1 diabetes." PLoS genetics 8 (9) doi:10.1371/journal.pgen.1002921
Lambers Heerspink Hiddo J, Holtkamp Frank A, Parving Hans-Henrik, Navis Gerjan J, Lewis Julia B, et al. 2012. "Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers." Kidney international 82 (3) doi:10.1038/ki.2012.74
Nielsen Stine E, Reinhard Henrik, Zdunek Dietmar, Hess Georg, Gutiérrez Orlando M, et al. 2012. "Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients." Diabetes research and clinical practice 97 (1) doi:10.1016/j.diabres.2012.02.007
Persson Frederik, Lewis Julia B, Lewis Edmund J, Rossing Peter, Hollenberg Norman K, Parving Hans-Henrik 2012. "Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study." Journal of the renin-angiotensin-aldosterone system : JRAAS 13 (2) doi:10.1177/1470320312437068
Rabbani Naila, Adaikalakoteswari Antonysunil, Rossing Kasper, Rossing Peter, Tarnow Lise, et al. 2012. "Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria." Amino acids 42 (5) doi:10.1007/s00726-011-0857-7
Persson Frederik, Rathcke Camilla Noelle, Gall Mari-Anne, Parving Hans-Henrik, Vestergaard Henrik, Rossing Peter 2012. "High YKL-40 levels predict mortality in patients with type 2 diabetes." Diabetes research and clinical practice 96 (1) doi:10.1016/j.diabres.2011.12.008
Nielsen Stine E, Rossing Kasper, Hess Georg, Zdunek Dietmar, Jensen Berit R, et al. 2012. "The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP." Scandinavian journal of clinical and laboratory investigation 72 (2) doi:10.3109/00365513.2011.645055
Dwyer Jamie P, Parving Hans-Henrik, Hunsicker Lawrence G, Ravid Moti, Remuzzi Giuseppe, Lewis Julia B 2012. "Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study." Cardiorenal medicine 2 (1) doi:000333249
Reinhard Henrik, Hansen Peter R, Wiinberg Niels, Kjær Andreas, Petersen Claus L, et al. 2012. "NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients." Cardiovascular diabetology 11 doi:10.1186/1475-2840-11-19
Joergensen Christel, Reinhard Henrik, Schmedes Anne, Hansen Peter R, Wiinberg Niels, et al. 2012. "Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate." Diabetes care 35 (1) doi:10.2337/dc11-1372
Kristensen Peter Lommer, Pedersen-Bjergaard Ulrik, Beck-Nielsen Henning, Nørgaard Kirsten, Perrild Hans, et al. 2012. "A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design." BMC endocrine disorders 12 doi:10.1186/1472-6823-12-10
Reinhard Henrik, Garde Ellen, Skimminge Arnold, Åkeson Per, Ramsøy Thomas Zoëga, et al. 2012. "Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients." Cardiovascular diabetology 11 doi:10.1186/1475-2840-11-119

2011

Skali Hicham, Parving Hans-Henrik, Parfrey Patrick S, Burdmann Emmanuel A, Lewis Eldrin F, et al. 2011. "Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience." Circulation 124 (25) doi:10.1161/CIRCULATIONAHA.111.030411
Engelen Lian, Persson Frederik, Ferreira Isabel, Rossing Peter, Hovind Peter, et al. 2011. "Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 26 (11) doi:10.1093/ndt/gfr102
Syreeni Anna, El-Osta Assam, Forsblom Carol, Sandholm Niina, Parkkonen Maikki, et al. 2011. "Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes." Diabetes 60 (11) doi:10.2337/db11-0073
Cangemi Claudia, Skov Vibe, Poulsen Michael Kjaer, Funder Jonas, Twal Waleed O, et al. 2011. "Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes." Clinical chemistry 57 (11) doi:10.1373/clinchem.2011.162966
Desai Akshay S, Toto Robert, Jarolim Petr, Uno Hajime, Eckardt Kai-Uwe, et al. 2011. "Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD." American journal of kidney diseases : the official journal of the National Kidney Foundation 58 (5) doi:10.1053/j.ajkd.2011.05.020
Reinhard Henrik, Hansen Peter R, Persson Frederik, Tarnow Lise, Wiinberg Niels, et al. 2011. "Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 26 (10) doi:10.1093/ndt/gfr009
Weir Matthew R, Hollenberg Norman K, Remuzzi Giuseppe, Zappe Dion H, Meng Xiangyi, Parving Hans-Henrik 2011. "Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients." Journal of hypertension 29 (10) doi:10.1097/HJH.0b013e32834a8a25
McMurray John J V, Uno Hajime, Jarolim Petr, Desai Akshay S, de Zeeuw Dick, et al. 2011. "Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)." American heart journal 162 (4) doi:10.1016/j.ahj.2011.07.016
Hellemons Merel E, Persson Frederik, Bakker Stephan J L, Rossing Peter, Parving Hans-Henrik, et al. 2011. "initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial." Diabetes care 34 (9) doi:10.2337/dc11-0324
Holtkamp Frank A, de Zeeuw Dick, Thomas Merlin C, Cooper Mark E, de Graeff Pieter A, et al. 2011. "An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function." Kidney international 80 (3) doi:10.1038/ki.2011.79
Miao Yan, Ottenbros Stefan A, Laverman Goos D, Brenner Barry M, Cooper Mark E, et al. 2011. "Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial." Hypertension 58 (1) doi:10.1161/HYPERTENSIONAHA.111.171488
Astor Brad C, Matsushita Kunihiro, Gansevoort Ron T, van der Velde Marije, Woodward Mark, et al. 2011. "Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts." Kidney international 79 (12) doi:10.1038/ki.2010.550
Holtkamp Frank A, de Zeeuw Dick, de Graeff Pieter A, Laverman Gozewijn D, Berl Tom, et al. 2011. "Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials." European heart journal 32 (12) doi:10.1093/eurheartj/ehr017
Möllsten Anna, Vionnet Nathalie, Forsblom Carol, Parkkonen Maija, Tarnow Lise, et al. 2011. "A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women." Molecular genetics and metabolism 103 (1) doi:10.1016/j.ymgme.2011.01.004
Persson Frederik, Lewis Julia B, Lewis Edmund J, Rossing Peter, Hollenberg Norman K, Parving Hans-Henrik 2011. "Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy." Clinical journal of the American Society of Nephrology : CJASN 6 (5) doi:10.2215/CJN.07590810
Nielsen Stine E, Andersen Steen, Zdunek Dietmar, Hess Georg, Parving Hans-Henrik, Rossing Peter 2011. "Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy." Kidney international 79 (10) doi:10.1038/ki.2010.554
Joergensen Christel, Hovind Peter, Schmedes Anne, Parving Hans-Henrik, Rossing Peter 2011. "Vitamin D levels, microvascular complications, and mortality in type 1 diabetes." Diabetes care 34 (5) doi:10.2337/dc10-2459
Broedbaek Kasper, Henriksen Trine, Weimann Allan, Petersen Morten, Andersen Jon T, et al. 2011. "Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy." Diabetes care 34 (5) doi:10.2337/dc10-2214
Engelen Lian, Lund Søren S, Ferreira Isabel, Tarnow Lise, Parving Hans-Henrik, et al. 2011. "Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes." European journal of endocrinology / European Federation of Endocrine Societies 164 (3) doi:10.1530/EJE-10-0851
Nin Johanna W, Jorsal Anders, Ferreira Isabel, Schalkwijk Casper G, Prins Martin H, et al. 2011. "Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study." Diabetes care 34 (2) doi:10.2337/dc10-1087
Lund Søren S, Petersen Martin, Frandsen Merete, Smidt Ulla M, Parving Hans-Henrik, et al. 2011. "Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus." Clinical chemistry 57 (2) doi:10.1373/clinchem.2009.133868
Wessman Maija, Forsblom Carol, Kaunisto Mari A, Söderlund Jenny, Ilonen Jorma, et al. 2011. "Novel susceptibility locus at 22q11 for diabetic nephropathy in type 1 diabetes." PloS one 6 (9) doi:10.1371/journal.pone.0024053
Hovind Peter, Rossing Peter, Johnson Richard J, Parving Hans-Henrik 2011. "Serum uric acid as a new player in the development of diabetic nephropathy." Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 21 (1) doi:10.1053/j.jrn.2010.10.024
Reinhard Henrik, Jacobsen Peter Karl, Lajer Maria, Tarnow Lise, Astrup Anne Sofie, et al. 2011. "Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy." Nephron. Clinical practice 118 (3) doi:10.1159/000322667
Nielsen Stine Elkjaer, Hansen Henrik Post, Jensen Berit Ruud, Parving Hans-Henrik, Rossing Peter 2011. "Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study." Nephron. Clinical practice 118 (2) doi:10.1159/000320615
Reinhard Henrik, Wiinberg Niels, Hansen Peter R, Kjær Andreas, Petersen Claus L, et al. 2011. "NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis." Cardiovascular diabetology 10 doi:10.1186/1475-2840-10-71
Reinhard Henrik, Nybo Mads, Hansen Peter R, Wiinberg Niels, Kjær Andreas, et al. 2011. "Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria." Cardiovascular diabetology 10 doi:10.1186/1475-2840-10-70
Dendooven Amélie, Nguyen Tri Q, Brosens Lodewijk, Li Dongxia, Tarnow Lise, et al. 2011. "The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes." Journal of negative results in biomedicine 10 doi:10.1186/1477-5751-10-4

2010

Reinhard Henrik, Lajer Maria, Gall Mari-Anne, Tarnow Lise, Parving Hans-Henrik, et al. 2010. "Osteoprotegerin and mortality in type 2 diabetic patients." Diabetes care 33 (12) doi:10.2337/dc10-0858
de Zeeuw Dick, Agarwal Rajiv, Amdahl Michael, Audhya Paul, Coyne Daniel, et al. 2010. "Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial." Lancet 376 (9752) doi:10.1016/S0140-6736(10)61032-X
Delles Christian, Schiffer Eric, von Zur Muhlen Constantin, Peter Karlheinz, Rossing Peter, et al. 2010. "Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals." Journal of hypertension 28 (11) doi:10.1097/HJH.0b013e32833d81b7
Persson Frederik, Lewis Julia B, Lewis Edmund J, Rossing Peter, Hollenberg Norman K, Parving Hans-Henrik 2010. "Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy." Diabetes care 33 (11) doi:10.2337/dc10-0833
Joergensen Christel, Gall Mari-Anne, Schmedes Anne, Tarnow Lise, Parving Hans-Henrik, Rossing Peter 2010. "Vitamin D levels and mortality in type 2 diabetes." Diabetes care 33 (10) doi:10.2337/dc10-0582
Nin Johanna W M, Jorsal Anders, Ferreira Isabel, Schalkwijk Casper G, Prins Martin H, et al. 2010. "Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study." Diabetes 59 (8) doi:10.2337/db09-1509
Lajer Maria, Jorsal Anders, Tarnow Lise, Parving Hans-Henrik, Rossing Peter 2010. "Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy." Diabetes care 33 (7) doi:10.2337/dc09-2174
Nielsen Stine Elkjaer, Sugaya Takeshi, Hovind Peter, Baba Tsuneharu, Parving Hans-Henrik, Rossing Peter 2010. "Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients." Diabetes care 33 (6) doi:10.2337/dc09-2242
Maeda Shiro, Kobayashi Masa-aki, Araki Shin-ichi, Babazono Tetsuya, Freedman Barry I, et al. 2010. "A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes." PLoS genetics 6 (2) doi:10.1371/journal.pgen.1000842
Andersen Sten, Mischak Harald, Zürbig Petra, Parving Hans-Henrik, Rossing Peter 2010. "Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria." BMC nephrology 11 doi:10.1186/1471-2369-11-29
Lajer Maria, Tarnow Inge, Michelson Alan D, Jorsal Anders, Frelinger Andrew L, et al. 2010. "Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function." Platelets 21 (7) doi:10.3109/09537104.2010.500422
Weir Matthew R, Hollenberg Norman K, Zappe Dion H, Meng Xiangyi, Parving Hans-Henrik, et al. 2010. "Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria." Journal of hypertension 28 (1) doi:10.1097/HJH.0b013e328332bd61

2009

Pfeffer Marc A, Burdmann Emmanuel A, Chen Chao-Yin, Cooper Mark E, de Zeeuw Dick, et al. 2009. "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease." The New England journal of medicine 361 (21) doi:10.1056/NEJMoa0907845
Schjoedt Katrine J, Christensen Per K, Jorsal Anders, Boomsma Frans, Rossing Peter, Parving Hans-Henrik 2009. "Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 24 (11) doi:10.1093/ndt/gfp311
Tarnow Inge, Michelson Alan D, Barnard Marc R, Frelinger Andrew L, Aasted Bent, et al. 2009. "Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity." Platelets 20 (7) doi:10.3109/09537100903221001
Persson Frederik, Rossing Peter, Reinhard Henrik, Juhl Tina, Stehouwer Coen D A, et al. 2009. "Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria." Diabetes care 32 (10) doi:10.2337/dc09-0168
Delea Thomas E, Sofrygin Oleg, Palmer James L, Lau Helen, Munk Veronica C, et al. 2009. "Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria." Journal of the American Society of Nephrology : JASN 20 (10) doi:10.1681/ASN.2008111144
Nielsen Stine E, Sugaya Takeshi, Tarnow Lise, Lajer Maria, Schjoedt Katrine J, et al. 2009. "Tubular and glomerular injury in diabetes and the impact of ACE inhibition." Diabetes care 32 (9) doi:10.2337/dc09-0429
Bilous Rudy, Chaturvedi Nish, Sjølie Anne Katrin, Fuller John, Klein Ronald, et al. 2009. "Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials." Annals of internal medicine 151 (1) doi:
Klausen Klaus Peder, Parving Hans-Henrik, Scharling Henrik, Jensen Jan Skov 2009. "Microalbuminuria and obesity: impact on cardiovascular disease and mortality." Clinical endocrinology 71 (1) doi:10.1111/j.1365-2265.2008.03427.x
Pfeffer Marc A, Burdmann Emmanuel A, Chen Chao-Yin, Cooper Mark E, de Zeeuw Dick, et al. 2009. "Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)." American journal of kidney diseases : the official journal of the National Kidney Foundation 54 (1) doi:10.1053/j.ajkd.2009.04.008
Hovind Peter, Rossing Peter, Tarnow Lise, Johnson Richard J, Parving Hans-Henrik 2009. "Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study." Diabetes 58 (7) doi:10.2337/db09-0014
Robinson Jennifer G, Ballantyne Christie M, Grundy Scott M, Hsueh Willa A, Parving Hans-Henrik, et al. 2009. "Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)." The American journal of cardiology 103 (12) doi:10.1016/j.amjcard.2009.05.003
Parving Hans-Henrik, Brenner Barry M, McMurray John J V, de Zeeuw Dick, Haffner Steven M, et al. 2009. "Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 24 (5) doi:10.1093/ndt/gfn721
Fellström Bengt C, Jardine Alan G, Schmieder Roland E, Holdaas Hallvard, Bannister Kym, et al. 2009. "Rosuvastatin and cardiovascular events in patients undergoing hemodialysis." The New England journal of medicine 360 (14) doi:10.1056/NEJMoa0810177
Advani Andrew, Gilbert Richard E, Thai Kerri, Gow Renae M, Langham Robyn G, et al. 2009. "Expression, localization, and function of the thioredoxin system in diabetic nephropathy." Journal of the American Society of Nephrology : JASN 20 (4) doi:10.1681/ASN.2008020142
Kjaer Andreas, Kristoffersen Ulrik Sloth, Tarnow Lise, Parving Hans-Henrik, Hesse Birger 2009. "Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients." Diabetes research and clinical practice 84 (1) doi:10.1016/j.diabres.2009.01.010
Parving Hans-Henrik, Persson Frederik, Lewis Julia B, Lewis Edmund J, Hollenberg Norman K 2009. "[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]." Ugeskrift for laeger 171 (11) doi:
Hu Yaomin, Kaisaki Pamela J, Argoud Karène, Wilder Steven P, Wallace Karin J, et al. 2009. "Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus." BMC medical genomics 2 doi:10.1186/1755-8794-2-41
Lund Søren S, Tarnow Lise, Frandsen Merete, Nielsen Bente B, Hansen Birgitte V, et al. 2009. "Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial." BMJ (Clinical research ed.) 339 doi:

2008

Trégouet David-Alexandre, Groop Per-Henrik, McGinn Steven, Forsblom Carol, Hadjadj Samy, et al. 2008. "G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetes." Diabetes 57 (10) doi:10.2337/db08-0073
Jorsal Anders, Tarnow Lise, Frystyk Jan, Lajer Maria, Flyvbjerg Allan, et al. 2008. "Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy." Kidney international 74 (5) doi:10.1038/ki.2008.201
Gaede Peter, Valentine William J, Palmer Andrew J, Tucker Daniel M D, Lammert Morten, et al. 2008. "Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study." Diabetes care 31 (8) doi:10.2337/dc07-2452
Leth Henrik, Andersen Kristian K, Frystyk Jan, Tarnow Lise, Rossing Peter, et al. 2008. "Elevated levels of high-molecular-weight adiponectin in type 1 diabetes." The Journal of clinical endocrinology and metabolism 93 (8) doi:10.1210/jc.2008-0360
Parving Hans-Henrik, Persson Frederik, Lewis Julia B, Lewis Edmund J, Hollenberg Norman K 2008. "Aliskiren combined with losartan in type 2 diabetes and nephropathy." The New England journal of medicine 358 (23) doi:10.1056/NEJMoa0708379
Astrup Anne Sofie, Tarnow Lise, Pietraszek Lotte, Schalkwijk Casper G, Stehouwer Coen D A, et al. 2008. "Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate." Diabetes care 31 (6) doi:10.2337/dc07-1960
Nguyen Tri Q, Tarnow Lise, Jorsal Anders, Oliver Noelynn, Roestenberg Peggy, et al. 2008. "Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy." Diabetes care 31 (6) doi:10.2337/dc07-2469
Astrup Anne Sofie, Kim Won Yong, Tarnow Lise, Botnar René M, Simonsen Cheryl, et al. 2008. "Relation of left ventricular function, mass, and volume to NT-proBNP in type 1 diabetic patients." Diabetes care 31 (5) doi:10.2337/dc07-1536
Lund Søren S, Tarnow Lise, Stehouwer Coen D A, Schalkwijk Casper G, Teerlink Tom, et al. 2008. "Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes." European journal of endocrinology / European Federation of Endocrine Societies 158 (5) doi:10.1530/EJE-07-0815
Lajer Maria, Tarnow Lise, Jorsal Anders, Teerlink Tom, Parving Hans-Henrik, Rossing Peter 2008. "Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy." Diabetes care 31 (4) doi:10.2337/dc07-1762
Parving Hans-Henrik, de Zeeuw Dick, Cooper Mark E, Remuzzi Giuseppe, Liu Nancy, et al. 2008. "ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy." Journal of the American Society of Nephrology : JASN 19 (4) doi:10.1681/ASN.2007050582
Joseph Gowsini, Tarnow Lise, Astrup Anne Sofie, Hansen Troels Krarup, Parving Hans-Henrik, et al. 2008. "Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients." The Journal of clinical endocrinology and metabolism 93 (4) doi:10.1210/jc.2007-1910
Tershakovec Andrew M, Keane William F, Zhang Zhongxin, Lyle Paulette A, Appel Gerald B, et al. 2008. "Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study." Diabetes care 31 (3) doi:10.2337/dc07-0196
Gaede Peter, Lund-Andersen Henrik, Parving Hans-Henrik, Pedersen Oluf 2008. "Effect of a multifactorial intervention on mortality in type 2 diabetes." The New England journal of medicine 358 (6) doi:10.1056/NEJMoa0706245
Lund Søren Søgaard, Tarnow Lise, Astrup Anne Sofie, Hovind Peter, Jacobsen Peter Karl, et al. 2008. "Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study." PloS one 3 (10) doi:10.1371/journal.pone.0003363
Persson Frederik, Rossing Peter, Hovind Peter, Stehouwer Coen D A, Schalkwijk Casper G, et al. 2008. "Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study." Scandinavian journal of clinical and laboratory investigation 68 (8) doi:10.1080/00365510802187226
Tarnow Lise, Groop Per-Henrik, Hadjadj Samy, Kazeem Gbenga, Cambien Francois, et al. 2008. "European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 23 (1) doi:10.1093/ndt/gfm501
Lund Søren S, Tarnow Lise, Frandsen Merete, Smidt Ulla M, Pedersen Oluf, et al. 2008. "Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes." European journal of endocrinology / European Federation of Endocrine Societies 158 (1) doi:10.1530/EJE-07-0500

2007

Astrup Anne Sofie, Nielsen Flemming S, Rossing Peter, Ali Samir, Kastrup Jens, et al. 2007. "Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study." Journal of hypertension 25 (12) doi:10.1097/HJH.0b013e3282f06428
Lajer Maria, Tarnow Lise, Jorsal Anders, Parving Hans-Henrik 2007. "Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 22 (11) doi:10.1093/ndt/gfm360
Hollenberg Norman K, Parving Hans-Henrik, Viberti Giancarlo, Remuzzi Giuseppe, Ritter Susan, et al. 2007. "Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus." Journal of hypertension 25 (9) doi:10.1097/HJH.0b013e328277596e
Eijkelkamp Wouter B A, Zhang Zhongxin, Remuzzi Giuseppe, Parving Hans-Henrik, Cooper Mark E, et al. 2007. "Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial." Journal of the American Society of Nephrology : JASN 18 (5) doi:10.1681/ASN.2006050445
Eijkelkamp Wouter B A, Zhang Zhongxin, Brenner Barry M, Cooper Mark E, Devereux Richard B, et al. 2007. "Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies." Journal of hypertension 25 (4) doi:10.1097/HJH.0b013e328014953c
Hadjadj Samy, Tarnow Lise, Forsblom Carol, Kazeem Gbenga, Marre Michel, et al. 2007. "Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations." Journal of the American Society of Nephrology : JASN 18 (4) doi:10.1681/ASN.2006101102
Kim Won Yong, Astrup Anne Sofie, Stuber Matthias, Tarnow Lise, Falk Erling, et al. 2007. "Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy." Circulation 115 (2) doi:10.1161/CIRCULATIONAHA.106.633339
Hovind Peter, Lamberts Steven, Hop Wim, Deinum Jaap, Tarnow Lise, et al. 2007. "An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes." European journal of endocrinology / European Federation of Endocrine Societies 156 (1) doi:10.1530/eje.1.02308

2006

Persson Frederik, Rossing Peter, Hovind Peter, Stehouwer Coen D A, Schalkwijk Casper, et al. 2006. "Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy." Diabetes 55 (12) doi:10.2337/db06-0827
Palmer Andrew J, Valentine William J, Tucker Daniel M D, Ray Joshua A, Roze Stéphane, et al. 2006. "A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension." Current medical research and opinion 22 (11) doi:10.1185/030079906X132730
Vionnet Nathalie, Tregouët David, Kazeem Gbenga, Gut Ivo, Groop Per-Henrik, et al. 2006. "Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene." Diabetes 55 (11) doi:10.2337/db06-0271
Hansen Troels Krarup, Gall Mari-Anne, Tarnow Lise, Thiel Steffen, Stehouwer Coen D, et al. 2006. "Mannose-binding lectin and mortality in type 2 diabetes." Archives of internal medicine 166 (18) doi:10.1001/archinte.166.18.2007
de Zeeuw Dick, Parving Hans-Henrik, Henning Robert H 2006. "Microalbuminuria as an early marker for cardiovascular disease." Journal of the American Society of Nephrology : JASN 17 (8) doi:10.1681/ASN.2006050517
Gardner Thomas W, Sander Birgit, Larsen Michael L, Kunselman Allen, Tenhave Thomas, et al. 2006. "An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial." Current eye research 31 (6) doi:10.1080/02713680600746112
Rossing Peter, Rossing Kasper, Gaede Peter, Pedersen Oluf, Parving Hans-Henrik 2006. "Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy." Diabetes care 29 (5) doi:10.2337/diacare.2951024
Astrup Anne Sofie, Tarnow Lise, Rossing Peter, Hansen Birgitte V, Hilsted Jannik, Parving Hans-Henrik 2006. "Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy." Diabetes care 29 (2) doi:
Rasmussen Lars Melholt, Tarnow Lise, Hansen Troels Krarup, Parving Hans-Henrik, Flyvbjerg Allan 2006. "Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients." European journal of endocrinology / European Federation of Endocrine Societies 154 (1) doi:10.1530/eje.1.02049
Nguyen Tri Q, Tarnow Lise, Andersen Steen, Hovind Peter, Parving Hans-Henrik, et al. 2006. "Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy." Diabetes care 29 (1) doi:

2005

Schjoedt Katrine Jordan, Rossing Kasper, Juhl Tina Ragnholm, Boomsma Frans, Rossing Peter, et al. 2005. "Beneficial impact of spironolactone in diabetic nephropathy." Kidney international 68 (6) doi:10.1111/j.1523-1755.2005.00756.x
Rossing Kasper, Schjoedt Katrine J, Jensen Berit R, Boomsma Frans, Parving Hans-Henrik 2005. "Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria." Kidney international 68 (3) doi:10.1111/j.1523-1755.2005.00511.x
Astrup Anne Sofie, Tarnow Lise, Rossing Peter, Pietraszek Lotte, Riis Hansen Peter, Parving Hans-Henrik 2005. "Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study." Kidney international 68 (3) doi:10.1111/j.1523-1755.2005.00521.x
Rossing Kasper, Schjoedt Katrine J, Smidt Ulla M, Boomsma Frans, Parving Hans-Henrik 2005. "Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study." Diabetes care 28 (9) doi:
Ahmed Sofia B, Hovind Peter, Parving Hans-Henrik, Rossing Peter, Price Deborah A, et al. 2005. "Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy." Diabetes care 28 (8) doi:
Rossing Kasper, Mischak Harald, Parving Hans-Henrik, Christensen Per K, Walden Michael, et al. 2005. "Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns." Kidney international 68 (1) doi:10.1111/j.1523-1755.2005.00394.x
Andersen Steen, van Nieuwenhoven Frans A, Tarnow Lise, Rossing Peter, Rossing Kasper, et al. 2005. "Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy." Kidney international 67 (6) doi:10.1111/j.1523-1755.2005.00337.x
Hovind Peter, Hansen Troels Krarup, Tarnow Lise, Thiel Steffen, Steffensen Rudi, et al. 2005. "Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study." Diabetes 54 (5) doi:
Andersen Gitte, Wegner Lise, Jensen Dorit Packert, Glümer Charlotte, Tarnow Lise, et al. 2005. "PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites." Hypertension 45 (4) doi:10.1161/01.HYP.0000158946.53289.24
Laverman Gozewijn Dirk, Andersen Steen, Rossing Peter, Navis Gerjan, de Zeeuw Dick, Parving Hans-Henrik 2005. "Renoprotection with and without blood pressure reduction." Kidney international. Supplement (94) doi:10.1111/j.1523-1755.2005.09414.x
Mix T-Christian H, Brenner Robert M, Cooper Mark E, de Zeeuw Dick, Ivanovich Peter, et al. 2005. "Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease." American heart journal 149 (3) doi:10.1016/j.ahj.2004.09.047
Sjølie Anne Katrin, Porta Massimo, Parving Hans-Henrik, Bilous Rudy, Klein Ronald 2005. "The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics." Journal of the renin-angiotensin-aldosterone system : JRAAS 6 (1) doi:10.3317/jraas.2005.003
Palmer Andrew J, Annemans Lieven, Roze Stéphane, Lapuerta Pablo, Chen Roland, et al. 2005. "Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria." Kidney international. Supplement (93) doi:10.1111/j.1523-1755.2005.09312.x
Tarnow Lise, Astrup Anne Sofie, Parving Hans-Henrik 2005. "Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy." Scandinavian journal of clinical and laboratory investigation. Supplementum 240 doi:10.1080/00365510500235970

2004

Gaede Peter, Tarnow Lise, Vedel Pernille, Parving Hans-Henrik, Pedersen Oluf 2004. "Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 19 (11) doi:10.1093/ndt/gfh470
Jacobsen Peter, Parving Hans-Henrik 2004. "Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy." Kidney international. Supplement (92) doi:10.1111/j.1523-1755.2004.09226.x
Rossing Kasper, Christensen Per K, Hovind Peter, Tarnow Lise, Rossing Peter, Parving Hans-Henrik 2004. "Progression of nephropathy in type 2 diabetic patients." Kidney international 66 (4) doi:10.1111/j.1523-1755.2004.00925.x
Hovind Peter, Tarnow Lise, Parving Hans-Henrik 2004. "Remission and regression of diabetic nephropathy." Current hypertension reports 6 (5) doi:
Hovind Peter, Tarnow Lise, Rossing Peter, Carstensen Bendix, Parving Hans-Henrik 2004. "Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy." Kidney international 66 (3) doi:10.1111/j.1523-1755.2004.00870.x
de Zeeuw Dick, Remuzzi Giuseppe, Parving Hans-Henrik, Keane William F, Zhang Zhongxin, et al. 2004. "Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy." Circulation 110 (8) doi:10.1161/01.CIR.0000139860.33974.28
Palmer Andrew J, Annemans Lieven, Roze Stéphane, Lamotte Mark, Lapuerta Pablo, et al. 2004. "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease." Diabetes care 27 (8) doi:
de Zeeuw Dick, Remuzzi Giuseppe, Parving Hans-Henrik, Keane William F, Zhang Zhongxin, et al. 2004. "Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL." Kidney international 65 (6) doi:10.1111/j.1523-1755.2004.00653.x
Hansen Troels K, Tarnow Lise, Thiel Steffen, Steffensen Rudi, Stehouwer Coen D, et al. 2004. "Association between mannose-binding lectin and vascular complications in type 1 diabetes." Diabetes 53 (6) doi:
Hovind Peter, Tarnow Lise, Rossing Peter, Jensen Berit Ruud, Graae Malene, et al. 2004. "Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study." BMJ (Clinical research ed.) 328 (7448) doi:10.1136/bmj.38070.450891.FE
Jacobsen Peter, Rossing Kasper, Parving Hans-Henrik 2004. "Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy." Current opinion in nephrology and hypertension 13 (3) doi:
Hesse Birger, Meyer Christian, Nielsen Flemming S, Sato Asako, Hove Jens D, et al. 2004. "Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition." European journal of nuclear medicine and molecular imaging 31 (3) doi:10.1007/s00259-003-1388-6
Tarnow Lise, Hovind Peter, Teerlink Tom, Stehouwer Coen D A, Parving Hans-Henrik 2004. "Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes." Diabetes care 27 (3) doi:
Parving Hans-Henrik, Andersen Steen, Jacobsen Peter, Christensen Per K, Rossing Kasper, et al. 2004. "Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points." Seminars in nephrology 24 (2) doi:

2003

Andersen Steen, Bröchner-Mortensen Jens, Parving Hans-Henrik 2003. "Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria." Diabetes care 26 (12) doi:
Jacobsen Peter, Tarnow Lise, Carstensen Bendix, Hovind Peter, Poirier Odette, Parving Hans-Henrik 2003. "Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy." Journal of the American Society of Nephrology : JASN 14 (11) doi:
Rossing Kasper, Jacobsen Peter, Pietraszek Lotte, Parving Hans-Henrik 2003. "Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial." Diabetes care 26 (8) doi:
Jacobsen Peter, Andersen Steen, Rossing Kasper, Jensen Berit R, Parving Hans-Henrik 2003. "Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy." Kidney international 63 (5) doi:10.1046/j.1523-1755.2003.00940.x
Andersen Steen, Tarnow Lise, Cambien Francois, Rossing Peter, Juhl Tina R, et al. 2003. "Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?" Diabetes care 26 (5) doi:
Hovind Peter, Tarnow Lise, Rossing Kasper, Rossing Peter, Eising Stefanie, et al. 2003. "Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes." Diabetes care 26 (4) doi:
Jacobsen Peter, Andersen Steen, Jensen Berit R, Parving Hans-Henrik 2003. "Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy." Journal of the American Society of Nephrology : JASN 14 (4) doi:
Rossing Kasper, Christensen Per K, Andersen Steen, Hovind Peter, Hansen Henrik Post, Parving Hans-Henrik 2003. "Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study." Diabetes care 26 (3) doi:
Hovind Peter, Rossing Peter, Tarnow Lise, Parving Hans-Henrik 2003. "Smoking and progression of diabetic nephropathy in type 1 diabetes." Diabetes care 26 (3) doi:
Gaede Peter, Hansen Henrik Post, Parving Hans-Henrik, Pedersen Oluf 2003. "Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 18 (3) doi:
Andersen Steen, Jacobsen Peter, Tarnow Lise, Rossing Peter, Juhl Tina R, Parving Hans-Henrik 2003. "Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 18 (2) doi:
Gaede Peter, Vedel Pernille, Larsen Nicolai, Jensen Gunnar V H, Parving Hans-Henrik, Pedersen Oluf 2003. "Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes." The New England journal of medicine 348 (5) doi:10.1056/NEJMoa021778
Rossing Kasper, Christensen Per K, Hansen Birgitte V, Carstensen Bendix, Parving Hans-Henrik 2003. "Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study." Diabetes care 26 (1) doi:
Christensen Per K, Akram Kamran, Kønig Karen B, Parving Hans-Henrik 2003. "Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy." Diabetes care 26 (1) doi:
Kjaer Andreas, Meyer Christian, Nielsen Flemming S, Parving Hans-Henrik, Hesse Birger 2003. "Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes." Journal of nuclear medicine : official publication, Society of Nuclear Medicine 44 (1) doi:

2002

Parving Hans-Henrik, Hovind Peter 2002. "Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy." Current hypertension reports 4 (5) doi:
Jacobsen Peter, Grarup Niels, Tarnow Lise, Parving Hans-Henrik, Pedersen Oluf 2002. "PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 17 (8) doi:
Andersen Steen, Rossing Peter, Juhl Tina R, Deinum Jaap, Parving Hans-Henrik 2002. "Optimal dose of losartan for renoprotection in diabetic nephropathy." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 17 (8) doi:
Andersen Steen, Tarnow Lise, Cambien Francois, Rossing Peter, Juhl Tina R, et al. 2002. "Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?" Kidney international 62 (1) doi:10.1046/j.1523-1755.2002.00410.x
Hansen Henrik Post, Tauber-Lassen Ellis, Jensen Berit R, Parving Hans-Henrik 2002. "Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy." Kidney international 62 (1) doi:10.1046/j.1523-1755.2002.00421.x
Jacobsen Peter, Andersen Steen, Rossing Kasper, Hansen Birgitte V, Parving Hans-Henrik 2002. "Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 17 (6) doi:
Rossing Peter, Hougaard Philip, Parving Hans-Henrik 2002. "Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study." Diabetes care 25 (5) doi:
Stehouwer Coen D A, Gall Mari-Anne, Twisk Jos W R, Knudsen Elisabeth, Emeis Jef J, Parving Hans-Henrik 2002. "Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death." Diabetes 51 (4) doi:
Flesner Per, Sander Birgit, Henning Vibeke, Parving Hans-Henrik, Dornonville de la Cour Morten, Lund-Andersen Henrik 2002. "Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications." Acta ophthalmologica Scandinavica 80 (1) doi:
Rossing Kasper, Christensen Per K, Jensen Berit R, Parving Hans-Henrik 2002. "Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study." Diabetes care 25 (1) doi:
Hansen Henrik P, Hovind Peter, Jensen Berit R, Parving Hans-Henrik 2002. "Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy." Kidney international 61 (1) doi:10.1046/j.1523-1755.2002.00092.x